当前位置： SCI文献检索 > RESPIRATORY RESEARCH期刊下所有文献 > High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial.

High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial.

Abstract：

BACKGROUND:High frequency chest wall oscillation (HFCWO) is used for airway mucus clearance. The objective of this study was to evaluate the use of HFCWO early in the treatment of adults hospitalized for acute asthma or chronic obstructive pulmonary disease (COPD). METHODS:Randomized, multi-center, double-masked phase II clinical trial of active or sham treatment initiated within 24 hours of hospital admission for acute asthma or COPD at four academic medical centers. Patients received active or sham treatment for 15 minutes three times a day for four treatments. Medical management was standardized across groups. The primary outcomes were patient adherence to therapy after four treatments (minutes used/60 minutes prescribed) and satisfaction. Secondary outcomes included change in Borg dyspnea score (≥ 1 unit indicates a clinically significant change), spontaneously expectorated sputum volume, and forced expired volume in 1 second. RESULTS:Fifty-two participants were randomized to active (n = 25) or sham (n = 27) treatment. Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70). Patient satisfaction was also similarly high in both groups. After four treatments, a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04). There were no significant differences in other secondary outcomes. CONCLUSIONS:HFCWO is well tolerated in adults hospitalized for acute asthma or COPD and significantly improves dyspnea. The high levels of patient satisfaction in both treatment groups justify the need for sham controls when evaluating the use of HFCWO on patient-reported outcomes. Additional studies are needed to more fully evaluate the role of HFCWO in improving in-hospital and post-discharge outcomes in this population. TRIAL REGISTRATION:ClinicalTrials.gov: NCT00181285.

journal_name

Respir Res

journal_title

Respiratory research

authors

Mahajan AK,Diette GB,Hatipoğlu U,Bilderback A,Ridge A,Harris VW,Dalapathi V,Badlani S,Lewis S,Charbeneau JT,Naureckas ET,Krishnan JA

doi

10.1186/1465-9921-12-120

subject

Has Abstract

pub_date

2011-09-10 00:00:00

pages

120

eissn

1465-9921

issn

1465-993X

pii

1465-9921-12-120

journal_volume

pub_type

杂志文章,多中心研究,随机对照试验

在线工具

High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial.